GlassScriptPhysician profile
Vincent A Chehval
NPI 1669785598
$2,532.78
in general payments reported to CMS, 2019-2025
36 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $99.65 · 2021: $328 · 2022: $509 · 2023: $454 · 2024: $443 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $323.55 | 2019-2024 | Moses 550 D\F\L, Lithovue |
| Urogen Pharma, INC. | $204.04 | 2020-2025 | Jelmyto |
| Procept Biorobotics Corporation | $186.76 | 2022-2025 | |
| Teleflex LLC | $152.37 | 2022-2024 | Urolift |
| Dornier Medtech America, INC | $135.08 | 2025 | Dornier Medtech |
| Ferring Pharmaceuticals INC. | $113.18 | 2024-2025 | Adstiladrin |
| Axonics, INC. | $105.81 | 2022 | |
| Astellas Pharma US INC | $98.03 | 2019-2023 | Myrbetriq |
| Baxter Healthcare | $93.86 | 2023-2024 | Floseal |
| Janssen Biotech, INC. | $85.22 | 2019-2024 | Erleada |
| Myriad Genetic Laboratories, INC. | $84.92 | 2021-2024 | Prolaris |
| Myovant Sciences INC. | $84.80 | 2021-2022 | |
| Abbvie INC. | $84.64 | 2021-2024 | Lupron Depot |
| Endo Pharmaceuticals INC. | $82.78 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $68.67 | 2023-2024 | Gemtesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $67.43 | 2022 | |
| Pfizer INC. | $51.92 | 2019 | |
| Convatec INC. | $51.39 | 2021 | |
| Tolmar, INC. | $43.32 | 2023-2025 | Eligard, Jatenzo |
| Progenics Pharmaceuticals, INC. | $41.59 | 2023-2024 | Pylarify |
| Antares Pharma, INC. | $37.12 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $36.43 | 2021-2025 | |
| Clarus Therapeutics INC. | $32.83 | 2021 | |
| Blue Earth Diagnostics | $32.31 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $30.79 | 2020-2022 | |
| Histosonics, INC. | $26.07 | 2024 | |
| Avadel Specialty Pharmaceuticals, LLC | $23.37 | 2019 | |
| Abbott Laboratories | $23.19 | 2022 | |
| Laborie Medical Technologies Corp. | $22.11 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Valencia Technologies Corporation | $22.04 | 2023 | Ecoin Device Kit |
| Ethicon US, LLC | $17.28 | 2019 | |
| Coloplast Corp | $14.67 | 2023 | Porges Coloplast |
| C. R. Bard, INC. & Subsidiaries | $14.45 | 2024 | Bard Urinary Drainage Bag |
| Travere Therapeutics, INC. | $14.36 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.63 | 2023 | Seglentis |
| Neotract INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Chehval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.